意大利布雷西亚SARS-CoV-2疫情期间透析与肾移植患者的管理
本文介绍意大利布雷西亚在SARS-CoV-2疫情中对透析和肾移植患者的管理经验。文章提出双相治疗策略:早期以抗病毒为主,后期以免疫抑制为主,并提供了临床与病理生理背景及初步结局数据。
要点
- COVID-19治疗建议双相策略:早期抗病毒,炎症期考虑免疫抑制
- 肾脏病患者尤其免疫抑制者管理更具挑战性
- 布雷西亚经验涵盖透析和肾移植患者
核心结论
- COVID-19管理趋向双相策略:症状出现7-10天内以病毒效应为主,可抗病毒治疗;随后炎症期可考虑糖皮质激素或抗细胞因子药物等免疫抑制策略。
研究设计与样本
- 本文为单中心经验总结,报告意大利布雷西亚对肾移植和血液透析患者的治疗管理及初步结局数据。
主要发现
- 第二炎症期以进行性肺受累、氧需求增加为特征,偶见噬血细胞综合征表现。
- 免疫抑制或合并严重共病的肾脏病患者管理更具挑战性。
临床怎么用
- 对透析和肾移植的COVID-19患者可参考双相策略分期治疗,早期抗病毒、后期酌情免疫抑制。
局限性
- 为单中心经验总结,初步结局数据;原文未报告具体样本量、效应值及统计显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease (COVID-19), is a major pandemic challenging health care systems around the world. The optimal management of patients infected with COVID-19 is still unclear, although the consensus is moving toward the need of a biphasic approach. During the first phase of the disease (from onset of the symptoms up to 7-10 days) viral-induced effects are prominent, with the opportunity to institute antiviral therapy. In the second inflammatory phase of the disease, immunosuppressive strategies (for example with glucocorticoids or anticytokine drugs) may be considered. This latter stage is characterized by the development of progressive lung involvement with increasing oxygen requirements and occasionally signs of the hemophagocytic syndrome. The management of the disease in patients with kidney disease is even more challenging, especially in those who are immunosuppressed or with severe comorbidities. Here we present the therapeutic approach used in Brescia (Italy) for managing patients infected with COVID-19 who underwent kidney transplantation and are receiving hemodialysis. Furthermore, we provide some clinical and physiopathological background, as well as preliminary outcome data of our cohort, to better clarify the pathogenesis of the disease and clinical management.
引用
- Alberici F, Delbarba E, Manenti C, et al. Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney Int Rep. 2020. PMID: 32292866. doi:10.1016/j.ekir.2020.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。